Lixte Biotechnology Holdings (FRA:8640) ROCE % : -280.56% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lixte Biotechnology Holdings's annualized ROCE % for the quarter that ended in Mar. 2025 was -280.56%.

Lixte Biotechnology Holdings ROCE % Historical Data

The historical data trend for Lixte Biotechnology Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings ROCE % Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-84.98

-142.33

-130.58

-108.91

-153.07

Lixte Biotechnology Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-108.52	-150.85	-213.73	-231.45	-280.56

Lixte Biotechnology Holdings ROCE % Calculation

Lixte Biotechnology Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-3.408	/	( ( (3.951 - 0.288)	+	(1.094 - 0.304) )	/ 2 )
	=	-3.408	/	( (3.663	+	0.79)	/ 2 )
	=	-3.408	/	2.2265
	=	-153.07 %

Lixte Biotechnology Holdings's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-2.612	/	( ( (1.094 - 0.304)	+	(1.4 - 0.328) )	/ 2 )
	=	-2.612	/	( ( 0.79	+	1.072 )	/ 2 )
	=	-2.612	/	0.931
	=	-280.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Lixte Biotechnology Holdings (FRA:8640) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lixte Biotechnology Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Headlines

No Headlines